ANCHOR
A New FDA-Approved Rescue Inhaler Treatment
Purpose
The purpose of the ANCHOR study is to assess how effective AIRSUPRA™—an FDA-approved rescue inhaler containing albuterol and budesonide—is in reducing severe asthma attacks (or exacerbations) in adults with asthma.
Albuterol helps to relax the smooth muscles of the airways, causing airways to widen, leading to easier breathing. Budesonide helps to decrease inflammation in the lungs. Inflammation in the lungs can lead to breathing difficulties.
Study Design
Participants will use AIRSUPRA™ for 12 months, which will be provided at no cost. During the 12-month use period, participants will be asked to complete electronic surveys every 3 months to answer questions related to their asthma symptoms and AIRSUPRA™ treatment. Participants will also be contacted by the study team every 3 months for safety monitoring.
Inclusion Criteria
Age 18 years and above
Diagnosed with asthma
At least 1 prescription filled for SABA-only inhaler (i.e., albuterol-only or levalbuterol-only) within the last 12 months
Had at least 1 asthma attack (exacerbation) treated with an oral or injectable steroid in the last 12 months
Had both medical and pharmacy insurance coverage for at least 12 months before enrollment and without foreseeable plans to discontinue coverage within 12 months
If female: must not be pregnant or breastfeeding.
All females of childbearing potential must use a highly effective form of birth control at the time of enrollment and until at least 14 days after the last dose of AIRSUPRA™ provided through the study.
Willingness to:
use AIRSUPRA™ as instructed by a physician
respond to quarterly electronic surveys via email or text
respond to quarterly safety inquiries from the study team
Exclusion Criteria
Major respiratory conditions other than asthma
(Conditions include: COPD, Cystic Fibrosis, Pulmonary Fibrosis, Bronchiectasis, Respiratory Tract Cancer, Bronchopulmonary Dysplasia, Sarcoidosis, Lung Cancer, Interstitial Lung Disease, Pulmonary Hypertension, and Tuberculosis)
Chronic use of oral corticosteroids (for any condition) within 3 months prior to enrollment.
History of AIRSUPRA™ use within the last 12 months
History of cancer (except for non-melanoma skin cancers) within the last 12 months
If female: currently pregnant or breastfeeding
Compensation
You will not be paid to participate in this research study. AIRSUPRA™ will be provided at no cost via a prescription voucher.
Additional Information
Have Questions?
Email the study team: